Nucleic acid recognizing Toll-like receptors as therapeutic targets: a focus on autoimmunity and cancer

References

• Early P, et al. An immunoglobulin heavy chain variable region gene is generated from three segments of DNA: VH, D and JH. Cell. 1980;19:981–992.
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, et al. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol. 2009;21:23–29.
   PubMed Web of Science ®Google Scholar
• Hoebe K, Beutler B. Forward genetic analysis of TLR-signaling pathways: an evaluation. AdvDrugDelivRev. 2008;60:824–829.
   Google Scholar
• Wagner H. Endogenous TLR ligands and autoimmunity. Adv Immunol. 2006;91:159–173.
   PubMed Web of Science ®Google Scholar
• Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev. 2008;223:271–283.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann NY Acad Sci. 2008;1143:1–20.
   PubMed Web of Science ®Google Scholar
• Beutler B. Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol Rev. 2009 ;227:248–263.
   Web of Science ®Google Scholar
• Netea MG, et al. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol. 2008;6:67–78.
   PubMed Web of Science ®Google Scholar
• Netea MG, et al. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol. 2004;172:3712–3718.
   PubMed Web of Science ®Google Scholar
• Yauch LE, et al. Involvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo. Infect Immun. 2004;72:5373–5382.
   PubMed Web of Science ®Google Scholar
• Biondo C, et al. MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus neoformans. Eur J Immunol. 2005;35:870–878.
   PubMed Web of Science ®Google Scholar
• Jin MS, Lee JO. Structures of the toll-like receptor family and its ligand complexes. Immunity. 2008;29:182–191.
   PubMed Web of Science ®Google Scholar
• Park BS, et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature. In press 2009.
   Google Scholar
• Liu L, et al. Structural basis of toll-like receptor 3 signaling with doublestranded RNA. Science. 2008;320:379–381.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol. 2009;21:317–337.
   PubMed Web of Science ®Google Scholar
• Zhang SY, et al. Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol Rev. 2007;220:225–236.
   Web of Science ®Google Scholar
• Bustamante J, et al. Novel primary immunodeficiencies revealed by the investigation of paediatric infectious diseases. Curr Opin Immunol. 2008;20:39–48.
   PubMed Web of Science ®Google Scholar
• Hacker H, et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature. 2006;439:204–207.
   PubMed Web of Science ®Google Scholar
• Hoshino K, et al. IkappaB kinase-alpha is critical for interferonalpha production induced by Toll-like receptors 7 and 9. Nature. 2006;440:949–953.
   PubMed Web of Science ®Google Scholar
• Lafyatis R, Marshak-Rothstein A. Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther. 2007;9:222.
   PubMed Web of Science ®Google Scholar
• Rivero SJ, et al. Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance. Arthritis Rheum. 1978;21:295–305.
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F, et al. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ. 2003;10:124–133.
   PubMed Web of Science ®Google Scholar
• Isnardi I. et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity. 2008;29:746–757.
   PubMed Web of Science ®Google Scholar
• Kono DH, Theofilopoulos AN. Genetics of SLE in mice. Springer Semin Immunopathol. 2006;28:83–96.
   PubMed Web of Science ®Google Scholar
• Okabe Y, et al. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J Exp Med. 2005;202:1333–1339.
   PubMed Web of Science ®Google Scholar
• Ehlers M, et al. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med. 2006;203:553–561.
   PubMed Web of Science ®Google Scholar
• Yu P et al. Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase C gamma 2 that specifically increases external Ca2+ entry. Immunity. 2005;22;451–465.
   Web of Science ®Google Scholar
• Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6:823–835.
   PubMed Web of Science ®Google Scholar
• Ma Z, et al. Modulation of autoimmunity by TLR9 in the chronic graft-vs-host model of systemic lupus erythematosus. J Immunol. 2006;177:7444–7450.
   Web of Science ®Google Scholar
• Pawar RD, et al. Ligands to nucleic acid-specific Toll-like receptors and the onset of lupus nephritis. J Am Soc Nephrol. 2006.
   Web of Science ®Google Scholar
• Christensen SR, et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006;25:417–428.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006;25:383–392.
   PubMed Web of Science ®Google Scholar
• Ronnblom L, Alm GV Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther. 2003;5:68–75.
   PubMed Web of Science ®Google Scholar
• Hron JD, Peng SL. Type I IFN protects against murine lupus. J Immunol. 2004;173:2134–2142.
   PubMed Web of Science ®Google Scholar
• Infante AJ, et al. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. J Pediatr.1998;133:629–633.
   Google Scholar
• Del-Rey M, et al. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. Blood. 2006;108:1306–1312.
   PubMed Web of Science ®Google Scholar
• Schwarting A, et al. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J Am Soc Nephrol. 2005;16:3264–3272.
   PubMed Web of Science ®Google Scholar
• Lau CM, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005;202:1171–1177.
   PubMed Web of Science ®Google Scholar
• Pisitkun P, et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006;312:1669–1672.
   PubMed Web of Science ®Google Scholar
• Meyers JA, et al. Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC. Cytokine. 2006;35:235–246.
   Web of Science ®Google Scholar
• Tabeta K, et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. NatImmunol. 2006;7:156–164.
   Google Scholar
• Fukui R, et al. Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing. J Exp Med. 2009;206:1339–1350.
   PubMed Web of Science ®Google Scholar
• Barrat FJ, et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol. 2007;37:3582–3586.
   PubMed Web of Science ®Google Scholar
• Takeshita F, Ishii KJ. Intracellular DNA sensors in immunity. Curr Opin Immunol. 2008;20:383–388.
   PubMed Web of Science ®Google Scholar
• Muruve DA, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature. 2008;452:103–107.
   PubMed Web of Science ®Google Scholar
• Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 2009;61:195–204.
   PubMed Web of Science ®Google Scholar
• Tluk S, et al. Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses. Int Immunol. 2009.
   Web of Science ®Google Scholar
• Herlands RA, et al. T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity. 2008;29:249–260.
   PubMed Web of Science ®Google Scholar
• Schlee M, et al. Approaching the RNA ligand for RIG-I? Immunol Rev. 2009;227:66–74.
   PubMed Web of Science ®Google Scholar
• Hornung V, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009;458:514–518.
   PubMed Web of Science ®Google Scholar
• Fernandes-Alnemri T, et al. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature. 2009;458:509–513.
   PubMed Web of Science ®Google Scholar
• Luo J, et al. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136:823–837.
   PubMed Web of Science ®Google Scholar
• Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83–117.
   PubMed Web of Science ®Google Scholar
• Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9:57–63.
   PubMed Web of Science ®Google Scholar
• Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol. 2007;19:203–208.
   PubMed Web of Science ®Google Scholar
• Kim S, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457:102–106.
   PubMed Web of Science ®Google Scholar
• Tsuji S, et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. InfectImmun. 2000;68:6883–6890.
   PubMed Web of Science ®Google Scholar
• Dunn GP, et al. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137–148.
   PubMed Web of Science ®Google Scholar
• Kim YM, et al. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature. 2008;452:234–238.
   PubMed Web of Science ®Google Scholar
• Tesniere A, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol. 2008;20:504–511.
   PubMed Web of Science ®Google Scholar
• Barton GM, et al. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol. 2006;7:49–56.
   PubMed Web of Science ®Google Scholar
• Jeannin P, et al. Pattern recognition receptors in the immune response against dying cells. Curr Opin Immunol. 2008;20:530–537.
   Web of Science ®Google Scholar
• Apetoh L, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220:47–59.
   PubMed Web of Science ®Google Scholar
• Broomfield SA, et al. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti- CD40 immunotherapy. J Immunol. 2009;182:5217–5224.
   PubMed Web of Science ®Google Scholar